Cited 0 time in
인테그린 α2와 상피성장인자수용체 차단항체의 저해작용을 통한 구강편평상피암 세포의 선택적 제거
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 최연식 | - |
| dc.contributor.author | 윤식 | - |
| dc.contributor.author | 김규천 | - |
| dc.contributor.author | 전영찬 | - |
| dc.contributor.author | 황대석 | - |
| dc.contributor.author | 김욱규 | - |
| dc.contributor.author | 변준호 | - |
| dc.contributor.author | 김철훈 | - |
| dc.contributor.author | 신상훈 | - |
| dc.date.accessioned | 2022-12-27T01:06:32Z | - |
| dc.date.available | 2022-12-27T01:06:32Z | - |
| dc.date.issued | 2013 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/21442 | - |
| dc.description.abstract | Purpose: This study was to find efficacy of integrin alpha2 (α2) and epidermal growth factor receptor (EGFR) as tumor marker of oral squamous cell carcinoma (SCC) and clarify the selective cell death effect of anti-integrin α2 and anti-EGFR on SCC cells, additionally testify conjugated gold nanoparticles (GNP) with air plasma for selective cell death of oral SCC. Methods: Expression of integrin α2, EGFR on human SCC cells (SCC25) were examined by western blot. SCC25 cells were treated with anti-integrin α2, anti-EGFR and analysed by Hemacolor staining, immunoflorescence staining, FACS flow cytometry. Conjugated GNP with integrin α2, EGFR antibody were treated by air plasma on SCC cells. Results: Integrin α2 and EGFR were over-expressed on SCC25 cells than normal lung WI-38 cells. The cell viability rate of SCC25 cells treated with anti-integrin α2, anti-EGFR was lower than WI-38 cells. The concentration changes of nucleus,releasing cytochrome c and apoptosis inducing factor (AIF) from mitochondria to cytosol were observed. The changes of proteins related with apoptosis were observed. Increase of bax, bcl-xL, activation of caspase-3, -7, -9, and fragmentation of PARP, DFF45 and decrease of lamin A/C in SCC25 cells were observed. In FACS, increase of sub-G1 and S phase was observed. Cell cycle related proteins, Such as cyclin D1, cyclin dependent kinase (CDK) 4, cyclin A, cyclin E, CDK 2, p27were decreased. After SCC25 cells treated with conjugatged GNP-Integrin α2, GNP-EGFR, additionally air plasma, the cell death rate was significantly increased. Conclusion: Integrin α2, EGFR were over-expressed in oral SCC cells. Anti-integrin α2, anti-EGFR in SCC25 cells induced apoptosis selectively. When GNP-anti integrin α2, GNP-anti EGFR were treated with air plasma on SCC25 cells, cancer cells were died more selectively. GNP-anti integrin α2, GNP-anti EGFR with air plasma could be treatment choice of oral SCC. | - |
| dc.format.extent | 12 | - |
| dc.language | 한국어 | - |
| dc.language.iso | KOR | - |
| dc.publisher | 대한악안면성형재건외과학회 | - |
| dc.title | 인테그린 α2와 상피성장인자수용체 차단항체의 저해작용을 통한 구강편평상피암 세포의 선택적 제거 | - |
| dc.title.alternative | Induction of Selective Cell Death of Oral Squamous Carcinoma Cells by Integrin α2 Antibody and EGFR Antibody | - |
| dc.type | Article | - |
| dc.identifier.bibliographicCitation | Maxillofacial Plastic Reconstructive Surgery, v.35, no.3, pp 143 - 154 | - |
| dc.citation.title | Maxillofacial Plastic Reconstructive Surgery | - |
| dc.citation.volume | 35 | - |
| dc.citation.number | 3 | - |
| dc.citation.startPage | 143 | - |
| dc.citation.endPage | 154 | - |
| dc.identifier.kciid | ART001772701 | - |
| dc.description.isOpenAccess | N | - |
| dc.subject.keywordAuthor | OSCC | - |
| dc.subject.keywordAuthor | Integrin alpha2 | - |
| dc.subject.keywordAuthor | EGFR | - |
| dc.subject.keywordAuthor | Gold nanoparticles | - |
| dc.subject.keywordAuthor | Cell death | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
